Devoted to natural ingredients
Founded in 2009, our goal was (and continues to be) to develop products based on key elements of the Mediterranean diet in combination with other natural ingredients that have been shown to support the body’s fight against inflammation.
The healthy effect of olive oil, a key element of the Mediterranean diet, has been extensively studied over the last several decades; many believe that olive oil polyphenols are one of the principal drivers of the health benefits typically attributed to the diet.
Our PureVida™ and OliPura™ line of products all incorporate a proprietary olive oil polyphenol extract, TrePhenol™, developed and clinically evaluated by Oliventures and its partners in Spain.
In addition to TrePhenol, Oliventures incorporates other high-quality ingredients in our nutritional supplements including:
- Marine Omega-3s: Sourced from a single-species, sustainably caught and refined in the U.S. fish oil. Omega-3s are another key element of the Mediterranean diet.
- Turmeric Curcumin: High-purity, sourced from the Turmeric root.
Table below indicates the amount of ingredients/serving.
|Product||TrePhenol†||Olive Polyphenols||Marine Omega-3s||Turmeric Curcumin|
|PureVida||375 mg||43.1 mg||750 mg||120 mg|
|OliPura Heart||187.5 mg||32.3 mg||1,000 mg||–|
|OliPura Joint||375 mg||64.5 mg||–||175 mg|
|OliPura Daily Living||300 mg||51.6 mg||–||–|
|OliPura Rx||600 mg||103.2 mg||–||–|
Dr. Michael Morse, Oliventures’ Chief Medical Officer, in conjunction with a medical team in Spain, developed the formulation for PureVida based on the Company’s preclinical research on TrePhenol and third-party evidence as to the potential benefits of coupling TrePhenol with marine omega-3s and high-purity curcumin. The team believes that the formulation has the potential to support the body’s response to inflammation. The clinical trial conducted by Oliventures in Spain (with 45 patients) sought to demonstrate that the unique combination of natural ingredients in PureVida can lower C-reactive protein (CRP) levels. CRP is a marker of inflammation produced by the liver and other organs in response to the release of certain pro-inflammatory substances by immune cells following injury or infection and other conditions associated with tissue injury and inflammation. The trial results demonstrated reduced levels of CRP and a reduction in joint pain in women taking aromatase inhibitors. Because only one trial, with 45 participants, has been performed (and the results have not yet been peer reviewed), more research is needed to confirm that the results of the one trial are valid.a